Parties Agree To Reschedule Xarelto Bellwether Trials to April

xarelto internal-bleedingThe four lawsuits that were to be tried first in the federal Xarelto products liability MDL No. 2592 were pushed back another month at the request of both plaintiffs and defendants.

The four Xarelto bellwether trials were initially set to begin this month in Louisiana’s Eastern District. They were rescheduled to begin in March after the NBA All-Star Games were moved to New Orleans in response to North Carolina’s controversial “bathroom bill.”

At both parties’ request, the bellwethers were delayed again and the first trial will now begin in April. The second, third, and fourth trials are scheduled to begin in the following months.

District Judge Eldon E. Fallon issued Case Management Order 2D on Jan. 30, laying out the bellwether trial schedule as follows:

  • First trial — April 24, 2017 in the Eastern District of Louisiana
  • Second trial — May 30, 2017 in the Eastern District of Louisiana
  • Third trial — To Be Set in June 2017 in the Southern District of Mississippi
  • Fourth trial — To Be Set in July 2017 in the Northern District of Texas

Four cases were chosen as bellwethers:

  1. Boudreaux, Jr. et al v. Janssen Research & Development LLC et al (2:14-cv-02720)
  2. Orr et al v. Janssen Research & Development LLC et al (2:15-cv-03708)
  3. Mingo v. Janssen Research & Development LLC et al (2:15-cv-03469)
  4. Henry v. Jansen Research & Development LLC et al (2:15-cv-00224)

Uncontrollable bleeding

There are 15,291 lawsuits consolidated in the massive Xarelto MDL as of Feb. 15.

The lawsuits stem from allegations that the anticoagulant Xarelto could cause uncontrollable bleeding in some people. They accuse the drug’s manufacturers — Bayer Healthcare and Johnson & Johnson subsidiary Janssen Pharmaceuticals — of failing to warn about Xarelto’s potential risks.

The first bellwether trial involves a Louisiana man with atrial fibrillation, who took Xarelto and suffered life-threatening gastrointestinal bleeding according to the Schmidt National Law Group in in San Diego.  Joseph Boudreaux Jr. took Xarelto for just under one month in 2014 before he was hospitalized for severe internal bleeding, according to the lawsuit.

He needed several blood transfusions and was hospitalized for five days as a result of his Xarelto bleeding episode. He then required follow-up medical treatment following his stay in the hospital.

Boudreaux filed a Xarelto lawsuit against Janssen and Bayer in December 2014, accusing the two manufacturers of concealing their knowledge of Xarelto’s defects from physicians and patients like himself.

His attorneys are set to square off against defendants Janssen and Bayer on April 24, 2017 in New Orleans.

 

 

Share this Post: